6 results about "Polydipsia" patented technology

The invention belongs to the technical field of polypeptide preparation and biological medicine, and particularly relates to a preparation method of Jingzhaotoxin polypeptide IX (JZTX-IX) and application of Jingzhaotoxin polypeptide IX in treatment of diabetes mellitus. A chilobrachys jingzhao toxin polypeptide IX coding gene, a 6 * His tag nucleotide sequence, a thrombin restriction enzyme cutting site nucleotide sequence and an MBP hydrotropy tag nucleotide sequence are connected to a prokaryotic expression vector for prokaryotic expression, and the expressed polypeptide is purified to obtain the chilobrachys jingzhao toxin polypeptide IX protein. The target polypeptide with high purity, complete disulfide bond folding and uniform conformation is obtained, so that the high purity and biological activity of the target polypeptide are ensured. On the basis, the treatment activity of the JZTX-IX on diabetes mellitus especially type II diabetes mellitus is found and verified, and the JZTX-IX can remarkably reduce fasting blood glucose of mice with the type II diabetes mellitus, improve glucose tolerance and insulin sensitivity, relieve polydipsia and polyuria symptoms and promote insulin secretion and islet cell proliferation.

The invention belongs to the technical field of polypeptide preparation and biological medicine, and particularly relates to a preparation method of Jingzhaotoxin polypeptide XI (JZTX-XI) and application of Jingzhaotoxin polypeptide XI (JZTX-XI) in treatment of diabetes mellitus. A Jingzhaotoxin polypeptide XI coding gene, a nucleotide sequence of a 6 * His tag, a nucleotide sequence of a thrombin restriction enzyme cutting site and a nucleotide sequence of an MBP hydrotropy tag are connected to a prokaryotic expression vector for prokaryotic expression, and a target polypeptide which is high in purity, complete in disulfide bond folding and uniform in conformation is obtained through purification. The purity and the biological activity are relatively high. Meanwhile, the treatment activity of the JZTX-XI in the aspect of diabetes is verified, and it is found that the JZTX-XI can remarkably reduce fasting blood glucose of mice with type II diabetes, remarkably up-regulate a glucose transport regulation gene Glut2, improve glucose tolerance and insulin sensitivity, relieve polydipsia and polyuria symptoms and promote insulin secretion and islet cell proliferation.

This invention discloses a medical repair hydrogel and its preparation method, specifically relating to the field of biomedical engineering technology. The hydrogel is a three-dimensional network structure formed by the synergistic self-assembly of glycyrrhizic acid and polydipsia glycoside through non-covalent bonds such as hydrogen bonding, hydrophobic interactions, and π-π stacking. No chemical cross-linking agent is required. It spontaneously forms a hydrogel upon heating to 70°C until completely dissolved and then cooling. It possesses reactive oxygen species-responsive structural dissociation characteristics, mechanical properties adapted to myocardial tissue, and a controllable degradation rate. This invention is suitable for intramyocardial drug administration after PCI, avoiding the shortcomings of traditional synthetic hydrogels that require external triggering and have unsuitable gelation conditions. Simultaneously, its three-dimensional network structure enables simultaneous long-term sustained release of the two active ingredients, with a 24-hour burst release rate of less than 25% and a cumulative release rate exceeding 70% within 7 days. This solves the problem of short half-lives and rapid clearance by body fluids of small molecule drugs, achieving continuous drug delivery to the lesion site.

The present application relates to a kind of traditional Chinese medicine composition of invigorating spleen and dampness and its preparation method and application, including the following weight parts of raw materials: 7-14 parts of ginseng, 10-20 parts of fried white bean, 10-20 parts of tuckahoe, 7-14 parts of orange peel, 15-30 parts of corn silk, 10-20 parts of gardenia, 12-24 parts of white lily root, 13-26 parts of kudzu root, 6-12 parts of white peony root, 6-12 parts of perilla leaf, 6-12 parts of shiitake mushroom, 1-4 parts of licorice root. It has the effect of invigorating spleen and dampness, ascending clear and descending turbid, promoting water and reducing swelling. It is used for body fatigue, limb soreness, edema, vomiting, diarrhea, polydipsia, loose stool and other symptoms caused by dampness. And it can be used as a health drink for chronic diseases related to dampness. The present application has a good application prospect with unique formula and no toxic side effects.

The invention discloses a construction method and application of a polycystic kidney disease mouse model. The invention provides a method for constructing a polycystic kidney mouse model, which comprises the following steps: inhibiting or reducing the expression quantity of a Talpid3 gene or / and the activity of a Talpid3 protein in renal tubular epithelial cells of a mouse to obtain a renal tubular epithelial cell specific Talpid3 gene knockout mouse; the polycystic kidney mouse model is obtained. According to the invention, a Talpid3 knockout mouse is constructed and cultivated, the Talpid3 knockout mouse is obviously reduced in body size and lighter in weight, the ratio of kidney to body weight is obviously increased, serious renal cyst appears along with serious renal dysfunction, urine concentration function decline and polydipsia and diuresis pathological manifestations, and the Talpid3 knockout mouse is successively dead 8 weeks after birth, so that the Talpid3 knockout mouse has no toxic or side effect. The typical symptoms of the polycystic kidney disease are shown, and the polycystic kidney disease mouse model is established.

Disclosed is an application of glycerol monodecanoate (GMD) in the preparation of a hypoglycemic drug or a functional food, falling within the technical field of medicine. According to the present disclosure, the hypoglycemic and insulin resistance-improving functions of GMD are first revealed. Studies demonstrate that GMD can enhance glucagon-like peptide-1 (GLP-1) secretion, activate hepatic glycolysis and insulin receptor (INSR)-related gene expression, while inhibiting hepatic gluconeogenesis pathway-related gene expression. Notably in type 2 diabetes mellitus (T2DM), glucose-lowering efficacy of GMD is comparable to metformin, and it outperforms metformin in regulating glucose tolerance and insulin tolerance, with significant alleviation of polydipsia. Moreover, as GMD is a naturally occurring edible substance with a high safety profile, it has a good application prospect in the preparation of a drug for treating hyperglycemia and diabetes, or a functional food to assist in lowering blood glucose.